All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

8

2023 to 2026

Breakthrough

0

Accelerated

0

Priority review

3

Orphan

2

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202310
202421
202510
202630

8 approvals

Newest first. Hover a badge for what it means.

  • Lisraya (Brepocitinib Tosylate) · Priovant TherapAug 27, 2026
    Original approval · NDA 220106NovelPriority reviewOrphanApproval letter

    To treat dermatomyositis in adults

  • Differin Epiduo Acne Gel (Adapalene and Benzoyl Peroxide) (Adapalene, Benzoyl Peroxide, Adapalene, Benzoyl Peroxide) · Galderma Labs LpMay 22, 2026
    Original approval · NDA 220736Approval letter
  • Adquey (Difamilast) · Acrotech BiopharmaFeb 12, 2026
    Original approval · NDA 219474NovelApproval letter

    To treat mild to moderate atopic dermatitis

  • Anzupgo (Delgocitinib) · Leo Pharma AsJul 23, 2025
    Original approval · NDA 219155NovelApproval letter

    To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response

  • Ebglyss (Lebrikizumab-Lbkz) · Eli Lilly and COSep 13, 2024
    Original approval · BLA 761306NovelApproval letter

    To treat moderate-to-severe atopic dermatitis

  • Sofdra (Sofpironium Bromide) · Botanix SbJun 18, 2024
    Original approval · NDA 217347NovelApproval letter

    To treat primary axillary hyperhidrosis

  • Zevtera (Ceftobiprole Medocaril Sodium) · IstxApr 3, 2024
    Original approval · NDA 218275NovelPriority reviewApproval letter

    To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia

  • Filsuvez (Birch Triterpenes) · ChiesiDec 18, 2023
    Original approval · NDA 215064NovelPriority reviewOrphanApproval letter

    To treat wounds associated with dystrophic and junctional epidermolysis bullosa

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.